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ABSTRACT
Introduction: Despite antiretroviral (ARV)
therapy reducing renal disease in human
immunodeficiency virus overall, there is
concern that certain ARVs, particularly
tenofovir disoproxil fumarate (TDF) with or
without a boosted protease inhibitor (PI), may
reduce renal function over time. It is not known
whether effects seen with PI-based regimens
are independent, result from interactions
with TDF coadministration, or are artefactual
owing to inhibition of renal tubular creatinine
transport by ritonavir or cobicistat
pharmacoenhancement. The aim of this
review was to conduct a systematic review of
studies, weighted toward high-quality evidence,
examining changes in renal function over time
with PI-based regimens.
Methods: PubMed, Embase, and Medline
databases and conference abstracts were
searched using pre-defined terms for English
language articles, published up to and including
August 12, 2013, describing changes in renal
function over time with PI-based regimens. All
available randomized controlled trials (RCTs)
were selected; however, to reduce bias, only
observational studies recruiting from more than
one center and analyzing data from more than
1,000 patients were included. Evidence was
qualitatively evaluated according to levels
established by the Oxford Centre for Evidence-
Based Medicine (OCEBM).
Results: A total of 2,322 articles were retrieved
by the initial search. Of these, 37 were selected
for full review, comprising 24 RCTs (OCEBM
Level 1 evidence: 4 reports of fully double-
blinded or blinded with respect to the PI
component). The remaining 20 RCTs and 13
observational studies qualified as OCEBM Level
2 evidence. Level 1 evidence showed initial but
non-progressive increases in serum creatinine
and corresponding decreases in estimated
glomerular filtration rate (eGFR), suggesting an
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effect on renal tubular transport of creatinine.
Level 2 evidence suggested that atazanavir and
lopinavir especially in combination with TDF
were associated with non-progressive
reductions in eGFR over time, with a decreased
risk for the development of chronic kidney
disease (CKD) on cessation and without the
development of advanced CKD or end-stage
renal disease (ESRD); whether these reductions
were independent or associated with
interactions with coadministered TDF could
not be established with certainty. Data on
darunavir were insufficient to draw any
conclusions. The principal limitation of the
reviewed studies was the lack of
standardization of creatinine measurements in
virtually all studies and the lack of corroborative
data on changes in proteinuria or other indices
of renal function.
Discussion: In this review, there was little
evidence for progressive changes in eGFR, or
the development of advanced CKD, or ESRD
with lopinavir or atazanavir. Further long-term
studies, employing a wide range of validated
renal function assessments, are required to fully
evaluate potential association of PIs with CKD.
Keywords: Chronic kidney disease; Glomerular
filtration rate; HIV infection; Protease
inhibitors; Renal function
INTRODUCTION
Overall, chronic kidney disease (CKD) has
declined in the combined antiretroviral
therapy (cART) era owing to declines in
human immunodeficiency virus (HIV)-
associated renal disease [1]. However, because
patients with HIV are now living longer [2],
CKD disease is proportionally becoming an
increasingly important cause of morbidity [3]
and mortality [4] in this population. The
prevalence of moderate or severe renal
impairment in patients with HIV infection,
defined as a sustained decrease in the
estimated glomerular filtration rate (eGFR)
to\60 mL/min/1.73 m2 for 3 months or more,
ranges from 3.5 to 9.7% [5], with rates of mild
renal impairment (eGFR 60–90 mL/min/m2)
being as high as 34.2% [6].
The causes of CKD in patients with HIV have
shifted away from HIV-associated nephropathy
(HIVAN) [7] toward associated coinfections,
such as hepatitis B and/or C [8], behavioral
risk factors, such as injecting drug use [9] or
over-the-counter medication use [10], and
probably most importantly, background
factors that also affect the general population,
such as aging, hypertension, and diabetes
[11–13].
Despite the overall benefit of antiretroviral
(ARV) therapy for the reduction of renal disease
in HIV [14], there is emerging concern that
certain ARVs [15], particularly tenofovir
disoproxil fumarate (TDF) [16] with or without
a boosted protease inhibitor (PI) [17], may be
associated with declines in renal function over
time.
Although some individual PIs such as
indinavir (IDV) are well known to cause acute
kidney injury (AKI) [18] and CKD [19], it is
much less certain whether other PIs are
associated with CKD either alone or in
interaction with nucleoside/nucleotide reverse-
transcriptase inhibitors (NRTI/NtRTIs) such as
TDF. The recent surge of low-quality evidence
in the form of small cohort studies and/or case
series reporting renal changes with PI use have
contributed to added concerns and confusion as
to how clinicians should respond.
There is also additional confusion as to the
most appropriate methods to measure renal
function in patients with HIV because the
commonly used creatinine-based estimating
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equations for glomerular filtration rate can be
biased in the context of HIV-related muscle
wasting [20].
There is, therefore, a need for clarity, based
on a review of high-quality evidence. The
aims of the current literature review were as
follows: via a qualitative data synthesis, to
critically evaluate evidence for changes in
renal function over time with the currently
used PIs such as atazanavir (ATV), darunavir
(DRV), fosamprenavir (FPV), lopinavir (LPV), or
saquinavir (SQV), when analyzed individually,
or as a class effect, or in interaction with TDF
coadministration.
METHODS
English language articles on randomized
controlled trials (RCTs) and observational
studies published over the last 10 years
containing data on changes in renal function
with the use of ATV, DRV, FPV, LPV, or SQV
were critically evaluated. This article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Definition of Renal Toxicity as Evaluated
in this Review
Articles were selected for review if they
contained longitudinal data examining CKD as
follows: (i) an increase in serum creatinine; and/
or (ii) a decrease in estimated creatinine
clearance (eCC) as estimated by the Cockcroft–
Gault (CG) equation [21]; and/or (iii) a decrease
in eGFR as assessed by the Modification of Diet
in Renal Disease (MDRD) [22], MDRD-4 [23], or
Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) [24] estimating
equations; and/or (iv) an increase in
proteinuria or urinary albumin:creatinine ratio
(ACR). In addition, we reported RCT
discontinuation rates due to renal adverse
events (AEs). Articles presenting data on AKI,
HIVAN, tubulopathies, or nephrolithiasis were
not selected.
In established guidelines from the Kidney
Disease Outcomes Quality Initiative (K/DOQI)
of the National Kidney Foundation CKD is
defined as either kidney damage or decreased
kidney function (decreased GFR\90 mL/min/
1.73 m2) for at least 3 months (Table 1) [25, 26].
More recently, the Kidney Disease Improving
Global Outcomes (KDIGO) 2012 guidelines
have introduced the concept of rapid
progression, defined as a sustained decline in
eGFR of more than 5 mL/min/1.73 m2/year [27].
Specific issues relating to the measurement of
renal function in patients with HIV-1 infection
and the relative merits of estimating equations
for creatinine clearance and GFR in this
population are summarized in the online
supplementary material section.
Other Inclusion and Exclusion Criteria
Further criteria for inclusion were as follows:
patients with HIV-1 infection; use of PI(s) that
are currently recommended in established US
and EU treatment guidelines as part of an ARV
regimen, either evaluated alone or in
comparison with regimens containing other
ARVs; RCTs (both double-blind or open-label
designs), observational studies, and meta-
analyses; English language articles; and a
publication date within the last 10 years up to
and including August 12, 2013. To reduce bias,
observational studies were included only if they
had recruited patients from more than one
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center and had analyzed data on at least 1,000
patients.
Further criteria for exclusion were as follows:
if the abstract was unavailable; animal studies;
case reports; presenting data in children and/or
adolescents \18 years of age; if a conference
abstract was superseded by journal publication;
if no useable AEs not leading to
discontinuation; if the article PDF was
unavailable; pharmacokinetic studies; articles
examining renal function as a predictor of other
outcomes, renal function in ART-naı¨ve patients,
or renal function posttransplantation; and
other review articles.
Search Strategy
The databases searched were Embase/Medline
through the OVID platform and PubMed over
the last 10 years up to and including August
12, 2013. Detailed search terms used for both
databases are shown in the online
supplementary material. Abstracts from the
Conference on Retroviruses and
Opportunistic Infections (CROI) and the
International AIDS Society (IAS) conference
were also hand-searched according to the
inclusion and exclusion criteria within the
same time frame. US and EU treatment
Table 1 National Kidney Foundation Kidney Disease Outcomes Quality Initiative Classiﬁcation, Prevalence, and Action




Prevalence (%)c Cumulative actions
1 Kidney damage with normal or
increased GFR
[90 3.3 Diagnosis and treatment:
Treatment of comorbid conditions
Slowing progression
Cardiovascular disease risk reduction
2 Kidney damage with mild
decreased GFR
60–89 3.0 Estimating progression
3 Moderately decreased GFR 30–59 4.3 Evaluating and treating complications
4 Severely decreased GFR 15–29 0.2 Preparation for kidney replacement therapy
5 Kidney failure \15 (or dialysis) 0.1 Kidney replacement (if uremia present)
Adapted from Levey et al. [25]
a Chronic kidney disease is deﬁned as either kidney damage or GFR less than 60 mL/min/1.73 m2 for 3 or more months.
Kidney damage is deﬁned as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests
or imaging studies. For stages 1 and 2, kidney damage is estimated using untimed urine samples to determine the
albumin:creatinine ratios; greater than 17 mg/g in men or greater than 25 mg/g in women on two measurements indicates
kidney damage
b Glomerular ﬁltration rate is estimated from serum creatinine measurements using the Modiﬁcation of Diet in Renal
Disease study equation based on age, sex, race, and calibration for serum creatinine
c Prevalence for stage 5 is from the US Renal Data System (1998); it includes approximately 230,000 patients treated with
dialysis and assumes 70,000 additional patients not receiving dialysis. Prevalence for stages 1–4 is from the Third National
Health and Nutrition Examination Survey (1988–1994). Population of 177 million adults aged 20 or more years. GFR
Glomerular ﬁltration rate
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guidelines were also consulted for relevant
information.
Because it was not always apparent on
abstract screening whether data on PI use
would be contained within the main body of
the article, a two-stage screening process was
adopted. First, abstracts were selected for full-
text retrieval according to the inclusion/
exclusion criteria, irrespective of whether PIs
were mentioned in the title/abstract or not.
Second, full-text articles were screened again
according to the inclusion/exclusion criteria
and were specifically excluded if they did not
contain data on currently recommended PIs.
Data Synthesis
Selected articles were weighted according the
Oxford Centre for Evidence-Based Medicine
Levels of Evidence 1 Table [28]: Level 1
evidence (meta-analyses and randomized
double-blind controlled trials); Level 2
evidence (randomized open-label clinical trials
or observational cohort studies with prospective
cohort studies being weighted above
retrospective studies); Level 3 evidence (case–
control studies); Level 4 evidence (case series);
Level 5 evidence (case reports or opinion). Level
4 or 5 evidence was not evaluated in this review.
Within each level of evidence, articles were
summarized using a clinically based approach:
firstly, studies in treatment-naı¨ve patients
versus treatment-experienced patients; and
second, studies without concomitant TDF use
versus with concomitant TDF use. No
quantitative data synthesis was performed.
Finally, the evidence obtained above was
balanced against indices of study quality
known to potentially bias reported outcomes
according to established methods [16, 29–32].
RESULTS
Articles Selected
A summary of the article selection process is
shown in the PRISMA flow diagram (Fig. 1). Of
the 37 articles selected for review, 24 described
RCTs, but only 4 of these reported RCTs were
fully double-blinded or blinded with respect to
the PI component and therefore qualified as
Level 1 evidence. The remaining 20 RCTs were
not blinded to the PI component or were open-
label studies and therefore qualified as Level 2
evidence. Observational studies meeting the
criteria for inclusion comprised a further 13
articles.
Level 1 Evidence (Meta-Analyses
and RCTs)
Meta-Analyses
No relevant meta-analyses were identified.
However, in one meta-analysis of studies
employing TDF, a subgroup analysis identified
that RCTs showed significantly smaller falls in
eGFR than observational studies [16]. This
finding is of relevance to this review and
could be interpreted in two ways. First,
randomization better equilibrates background
factors predisposing to CKD and, therefore,
RCTs give a more specific evaluation of the
influence of ARVs on kidney function; or
second, that observational clinical
populations contain real-life patients who
may exhibit a wider variety of clinical
comorbidities (often excluded in RCTs),
which may interact with ARVs to increase the
risk of CKD. Both of these interpretations may
be valid in different circumstances and thus,
both forms of evidence should be evaluated.
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Randomized Double-Blind Controlled Trials
Very few RCT reports were fully double-blinded
(n = 4), all concerned the use of ATV in
combination with TDF in treatment-naı¨ve
adults with HIV-1 infection, and are
summarized here under Level 1 evidence and
in Table 2. The remaining RCT reports were
randomized open-label studies (n = 19), which
are summarized under Level 2 evidence.
In two RCTs, the first comparing cobicistat
(COBI) versus ritonavir (RTV) as a
pharmacoenhancer of ATV both in
combination with emtricitabine (FTC) and
TDF [33] and the second comparing the
combined formulation ‘quad’ consisting of
elvitegravir (EVG)/COBI/FTC/TDF with RTV-
boosted ATV (ATV/r) ? FTC/TDF [34], eCC,
and eGFR were consistently decreased with
both COBI-containing and to a lesser extent
ATV/r-containing regimens at 48 weeks
(Table 2). In contrast, serum creatinine was
not elevated at 48 weeks with a regimen
consisting of efavirenz (EFV)/FTC/TDF in a
third RCT (Table 2). Given that both COBI and
to a lesser extent RTV inhibit the active tubular
secretion of creatinine [35], the changes in
serum creatinine, eCC, and eGFR are a likely
consequence of COBI and/or RTV components
rather than a direct effect of ATV on kidney
function. The rapid rise in serum creatinine
Records identified through database searching
(n = 2,298)
Additional records identified through hand 
searching conference abstracts (n = 24)
Records after duplicates removed
(n = 942)
Full-text articles assessed for 
eligibility
(n = 234)
Full-text articles excluded (n = 197) with reasons:
Case reports (n = 2)
Children/adolescents (n = 1) 
Conference abstract superseded by journal publication (n = 4)
Duplicate (n = 1)
HIVAN (n = 5)    
Non-HIV patients (n = 1)
Nephrolithiasis without evidence of renal impairment (n = 5)
No data on currently approved protease inhibitors (n = 97)
No relevant renal data (n = 8)
Observational single-centre study with <1,000 patients (n = 68)
PDF unobtainable (n = 2)
Pharmacokinetic study (n = 2)
Transplantation (n = 1)
Studies included in qualitative 
synthesis
(n = 37)
Records excluded (n = 708) with reasons:
Abstract unavailable (n = 22)
Acute kidney injury (n = 11)
Animal study (n = 2)
Case reports (n = 62)
Children/adolescents (n = 34)
Conference abstract superseded by journal publication (n = 2)
In vitro study (n = 10)
Inclusion criteria not met (n = 244)
Nephrolithiasis without evidence of renal impairment (n = 8)
No data on currently approved protease inhibitors (n = 46)
Non-English language (n = 2)
Non-HIV patients (n = 10)
Renal function as predictor of other outcomes (n = 6)
Renal function in ART-naïve patients (n = 10)







Records screened (n = 942)
Fig. 1 PRISMA ﬂow diagram. HIV Human immunodeﬁciency virus, HIVAN HIV-associated nephropathy
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over the first 2 weeks of treatment, followed by
stabilization at 8 weeks (see figure four, page
2,434, in DeJesus et al. [34]), with no further
change up to 96 weeks [36] would tend to
support this conclusion. However, given that
all regimens in these Level 1 studies also
contained TDF, an interaction with TDF can
neither be assumed nor ruled out.
Level 2 Evidence (Open-Label Clinical
Trials or Observational Cohort Studies)
Randomized Open-Label Clinical Trials
Treatment-Naı¨ve patients In studies
comparing ATV/r-containing regimens with
non-PI-containing regimens, the effect of
ATV/r on indices of renal function depended
upon the presence or absence of TDF
coadministration with ATV/r (Table 3A).
In the ARIES study (ClinicalTrials.gov
#NCT00440947), neither unboosted ATV nor
ATV/r was associated with changes in eGFR
(MDRD) after 144 weeks of exposure [37].
Similarly, within the ATV/r ? abacavir/
lamivudine (ABC/3TC) arm of AIDS Clinical
Trials Group (ACTG) A5202, eCC actually
increased at 96 weeks [38]. In contrast, within
the ATV/r ? FTC/TDF arm of ACTG A5202, eCC
significantly decreased [38]. Significant
decreases in eGFR (CKD-EPI) within the
ATV/r ? FTC/TDF arms were also observed
in the ALTAIR study (ClinicalTrials.gov
#NCT00335322) [39] and in the Albini et al.
[40] study, with the latter study employing
isotope dilution mass spectrometry (IDMS)
creatinine standardization and a confirmatory
multivariate analysis. These findings suggest
that ATV/r interacts with TDF resulting in
reductions in eCC and/or eGFR. However, the
Albini et al. [40] study did not demonstrate any
associated significant change in proteinuria and
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is between ATV and TDF or RTV and TDF.
Further studies are required to resolve this
question.
Regarding differences between ATV/r and
other boosted PI regimens, all of these studies
employed FTC/TDF backbones. For ATV/r versus
RTV-boosted DRV (DRV/r), RTV-boosted FPV
(FPV/r), or RTV-boosted LPV (LPV/r), the
magnitude of changes from baseline in eCC or
eGFR varied but were not significantly different
between the two PI/r regimens [41–43]. Using
mean change from baseline in eCC (CG), RTV-
boosted SQV (SQV/r) appeared to show greater
falls in eCC compared with ATV/r (Table 3B) [44].
In studies comparing LPV/r-containing
regimens with non-PI-containing regimens,
the effect of LPV/r on indices of renal function
depended upon the presence or absence of TDF
coadministration with LPV/r (Table 3C). In the
post hoc analysis from ACTG A5142, a
multivariate analysis showed greater declines
in eCC with LPV/r ? TDF/3TC compared with
EFV ? TDF/3TC [45]. Greater declines in eCC at
96 weeks were also observed in the LPV/
r ? TDF/FTC arm versus the LPV/r ? raltegravir
(RAL) arm in PROGRESS (ClinicalTrials.gov
#NCT00711009), with a larger proportion of
patients in the LPV/r ? RAL arm shifting to a
better CKD category at 96 weeks [46]. Similarly
in ACTG A5208, events of renal insufficiency
were higher in the LPV/r ? TDF/FTC arm versus
the nevirapine (NVP) ? TDF/FTC arm, a finding
that was confirmed on multivariate analyses
[47]. These findings suggest a similar conclusion
to that described for ATV/r, namely an
interaction between LPV/r and TDF, especially
since the post hoc ACTG A5142 analysis
identified relevant drug transporter
polymorphisms in whose presence TDF
exposures may be increased by LPV/r
inhibition of these transporters [45].
Treatment-Experienced Patients In six out of
the seven treatment-experienced studies
identified, there were no changes to the PI
component of the regimen; thus, it was not
possible to assess the contribution of the PI
component to changes in eGFR or eCC in these
studies [48–53].
In an open-label, randomized trial in
treatment-experienced patients receiving
highly active ARV therapy (HAART) for at least
6 months [the KITE study (ClinicalTrials.gov
#NCT00700115)], patients were randomized to
switch to RAL ? LPV/r (n = 40) or to remain on
their pre-existing HAART regimen (n = 20) [54].
At baseline, there were no statistically
significant differences in regimen components
between groups with approximately 40%
receiving LPV/r, 20% receiving other PIs, 40%
an NRTI and 60% TDF; however, baseline eCC
(CG equation) was significantly higher in the
RAL ? LPV/r group. Mean eCC at 48 weeks
adjusted for baseline value was 106.1 in the
RAL ? LPV/r group versus 115.9 mL/min in the
continuing HAART group (mean difference
9.7 mL/min; 95% CI -4.7, 24.2; P = 0.18).
Study limitations included open-label design,
small sample size, baseline imbalance in eCC
between groups, and the high proportion of
patients continuing on a PI in the HAART group
making changes in eCC consequent to
switching to RAL ? LPV/r difficult to interpret.
In summary, although adjusted mean eCC was
numerically higher in the continuing HAART
versus the RAL ? LPV/r group, absolute values
for eCC were higher in the RAL ? LPV/r group
by virtue of the imbalance in baseline eCC
between the two groups. In addition, the
adjusted mean difference was not significant.
It is, therefore, unlikely that the switch to LPV/r
was associated with meaningful changes in
kidney function.
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Observational Cohort Studies
Owing to the wide variety of study designs and
outcome measures employed, it was not
possible to meaningfully tabulate the
observational cohort studies. A summary
description of these studies is provided as
follows.
Treatment-Naı¨ve Patients Studies examining
individual PIs.
ATV with or without TDF: A population-based
Danish cohort study (n = 3,358) was conducted
to assess renal function and the incidence of
CKD, defined as two consecutive eGFR values
of\60 mL/min/1.73 m2 measured[3 months
apart, in patients with HIV infection over a
15-year period. At baseline, patients were
stratified on the basis of an eGFR (MDRD-4
equation) of\90 mL/min/1.73 m2 or C90 mL/
min/1.73 m2 [55]. In patients with a baseline
eGFR of\90 mL/min/1.73 m2, ATV (-2.00 mL/
min/1.73 m2; 95% CI -3.75, -0.25) and
TDF ? ATV (-4.06 mL/min/1.73 m2; 95% CI
-6.87, -1.25) were associated with reductions
in eGFR from baseline (linear mixed-effects
models). CKD incidence rate ratios (IRRs) were
estimated using a time-updated Cox-regression
model. The overall rate of CKD was low at 1.1
events per 100 patient-years. Female gender,
diabetes, hypertension, hepatitis C infection,
CD4 cell count\200 cells/lL at baseline, and
HIV diagnosis before 1995 were associated with
an increased risk of CKD, regardless of baseline
eGFR stratum. For patients with baseline
eGFR\90 mL/min/1.73 m2, HAART exposure
was associated with an increased risk of CKD
(IRR 6.08; 95% CI 2.76–13.41), but event rates
in those exposed to TDF (n = 7), TDF ? PIs
(n = 4), or TDF ? ATV (n = 10) were very low
limiting interpretability of findings in HAART
subgroups.
TDF and amprenavir, ATV, FPV, LPV/r, IDV,
nelfinavir, RTV, SQV, or tipranavir: The effects of
cumulative and ‘ever exposure’ to TDF and
interactions between TDF and PIs on renal
outcomes were evaluated in a retrospective
cohort study that included 10,841 patients
(from the Veterans Health Administration), all
of whom had started ARV treatment between
1997 and 2007 [56]. Associations between TDF
and time to first occurrence of proteinuria,
rapid decrease in renal function (C3 mL/min/
1.73 m2 every year), and CKD (eGFR\60 mL/
min/1.73 m2) were assessed using Cox
proportional hazards and marginal structural
models. During a median follow-up of
3.9–5.5 years, every year of TDF exposure was
associated with a 34% increase in proteinuria
risk (P\0.0001), a 33% increase in CKD risk
(P\0.0001), and an 11% increase in rapid
decrease in renal function risk (P = 0.0033),
which did not appear to lessen 6 months
following TDF discontinuation. In analyses
conducted to assess the effects of cumulative
exposure to other ARV drugs (including PIs),
IDV was the only PI that significantly increased
the risk of CKD.
Studies analyzing PIs as a class effect.
In the multicenter Canadian Observational
Cohort Study, patients with HIV infection
starting triple ARV therapy (n = 1,463) were
included in an analysis of markers of renal
function after a mean duration of follow-up of
24.6 months [57]. An increase in serum
creatinine to a level[120 lmol/L was seen
more frequently in patients taking PIs
compared with recipients of non-
nucleoside(nucleotide) reverse-transcriptase
inhibitors (NNRTIs); incidence rate (IR) 5.68 vs.
3.44 occurrences per 100 person-years of follow-
up, P = 0.02; however, it was unclear whether
PIs were used unboosted or boosted with RTV.
34 Infect Dis Ther (2015) 4:15–50
In the Center for AIDS Research Network of
Integrated Clinical Systems (CNICS)
multicenter study, risk factors for chronic
renal disease were evaluated in a large cohort
of HIV-infected persons (n = 3,329) initiating
ARV therapy and who were followed over
4 years [58]. RTV-boosted PI (PI/r) use (65%
amprenavir/r, 35% LPV/r) with TDF was
associated with a higher risk of moderate CKD
(eGFR of\60 mL/min/1.73 m2) and hazard odds
ratio was 3.35 (95% CI 1.40–8.02) in
multivariate-adjusted Cox proportional
models. In contrast, PI/r use (19% ATV/r, 69%
LPV/r, 6% other) without TDF was not
associated with an increase in moderate CKD
(hazard odds ratio 1.04; 95% CI 0.24–4.45).
Other factors associated with an increased risk
of CKD included Black race, coinfection with
hepatitis C virus, lower time-varying CD4? cell
count and higher time-varying HIV-1 RNA load.
In adjusted analyses of eGFR (MDRD and CKD-
EPI equations) using linear mixed-effects
models, ARV therapy overall was associated
with a significantly slower rate of decrease in
eGFR (from -2.18 pre ART to -1.37 mL/min/
1.73 m2 per year on ART; P = 0.02) without
evidence of an increased rate of decline in the
PI/r with TDF group.
In the ICONA Foundation cohort study,
eGFR (MDRD equation) was measured in
treatment-naı¨ve patients (n = 1,505) pre- and
post-ARV commencement [59]. Baseline eGFR
was\90 mL/min/1.73 m2 in 24% of patients;
age, female gender, hepatitis, CD4 count, and
diabetes pre-ARV therapy were significantly
associated with this eGFR level at baseline
(logistic regression). An eGFR decrease of[20%
from pre-combination ARV therapy levels was
identified in 96 patients (6.8 per 100 person-
years); older age, female gender, higher baseline
eGFR, and current treatment with didanosine
(DDI), TDF, or PIs (either unboosted or boosted
but not including IDV) were associated with an
eGFR decrease of[20% (Poisson regression).
However, the absence of ethnicity data to
compute eGFR using the MDRD equation
limited analysis validity, and the potential
interaction between TDF and PIs was not
specifically tested.
Patients with Mixed Treatment
Experience Studies examining individual PIs.
ATV and LPV: In the EuroSIDA cohort study,
HIV-infected patients were assessed for the
development of CKD over time from 2004
onwards (n = 6,843) [60]. CKD was defined as
either two measurements of B60 mL/min/
1.73 m2 taken C3 months apart for individuals
with a baseline eCC of[60 mL/min/1.73 m2, or
a confirmed 25% decrease in eCC for
individuals with a baseline eCC of B60 mL/
min/1.73 m2 (CG equation standardized for
body surface area). Sensitivity analyses using
the MDRD and CKD-EPI equations and the
International Network for Strategic Initiatives
in Global HIV Trials (INSIGHT) definition of
CKD were also performed. Factors associated
with the development of CKD were analyzed
using Poisson regression adjusted for traditional
factors known to be associated with CKD and
other potentially confounding variables. During
a median 3.7 years duration of follow-up, 225
(3.3%) developed CKD, equating to an
incidence of 1.05 per 100 person-years follow-
up. With increasing cumulative exposure to
TDF and ATV, there was an increased incidence
of CKD. The multivariate-adjusted IRRs per year
of exposure for TDF, ATV, and LPV/r were 1.16
(95% CI 1.06, 1.25; P\0.0001), 1.21 (95% CI
1.09, 1.34; P = 0.0003), and 1.08 (95% CI 1.01,
1.16; P = 0.03), respectively. Among covariates
included in the model, higher baseline eCC was
associated with a reduced risk of CKD; female
sex, older age, an AIDS-defining illness during
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follow-up, malignancy, hepatitis C infection,
hypertension, and diabetes were all associated
with an increased risk of CKD.
These results were robust to several
sensitivity analyses, using calculations based
on the MDRD and CKD-EPI equations; in
addition, possible interactive effects between
regimen components were tested by censoring
patient follow-up on starting TDF, ATV, or PI/r
(see figure three, page 1673, in Mocroft et al.
[60]). Thus for TDF-treated patients, the
adjusted IRR was slightly increased in patients
who had not started ATV, indicating that the
increased incidence of CKD with TDF cannot be
explained by concomitant ATV administration.
Although there was a slight decrease in adjusted
IRR in ATV-treated patients who had not started
TDF, the confidence intervals were too wide to
assess whether the increased incidence of CKD
with ATV therapy was attributable to
concomitant TDF administration.
Patients with prior but not current ATV or
LPV/r exposure did not have an increased
incidence of CKD compared with those with
no prior exposure to ATV or LPV/r, whereas
patients discontinuing TDF continued to have a
significantly increased incidence of CKD for up
to 12 months after discontinuation (see web
figure one b in Mocroft et al. [60]). The authors
concluded that changes in kidney function with
LPV/r and ATV were generally reversible on
cessation of these PIs.
In the prospective multinational D:A:D
cohort study, eCC (CG equation standardized
for body surface area) was used because
ethnicity data were restricted in several study
cohorts. Enrolled patients with HIV infection
(n = 22,603) and normal baseline renal function
(eCC of C90 mL/min/1.73 m2) were followed
from January 1, 2004 until they were
identified as having a confirmed eCC
of B70 mL/min/1.73 m2 (the hypothesized
point at which renal interventions and/or ARV
switching may be required) or a confirmed eCC
of B60 mL/min/1.73 m2 (indicating moderately
severe CKD) or until the final eCC measurement
during the follow-up period [61]. Poisson
regression models were used to determine
predictors and eCC-related discontinuations of
ARV treatment. During a median 4.5 years
duration of follow-up, an eCC of B70 mL/min/
1.73 m2 occurred in 2.1% of patients (IR
0.478 cases/100 person-years). CKD was
identified in 131 (0.6%) of patients (IR
0.133 cases/100 person-years). Compared with
patients with a current eCC of C90 mL/min/
1.73 m2, significantly higher rates of TDF
discontinuation (adjusted IRR 1.72; 95% CI
1.38, 2.14), but not other ARV drugs, were
identified in patients with a current eCC of
60–70 mL/min/1.73 m2. The cumulative use of
TDF (adjusted IRR 1.18/year; 95% CI 1.12, 1.25)
and ATV/r (adjusted IRR 1.19/year; 95% CI 1.09,
1.32) was independent predictor of a confirmed
eCC of B70 mL/min/1.73 m2, but not of CKD.
LPV/r was a significant predictor for a confirmed
eCC of B70 mL/min/1.73 m2 (adjusted IRR
1.11/year; 95% CI 1.05, 1.17) and CKD
(adjusted IRR 1.22/year; 95% CI 1.16, 1.28).
Censoring for use of other ARV drugs (including
abacavir) administered during the study or
before the start of the study (in the case of
treatment-experienced patients) did not affect
these results. Cumulative exposure to TDF,
ATV/r, and LPV/r increased IRRs for a change
in eCC from 90 to B70 mL/min/1.73 m2, which
nevertheless fell back to values approaching
unity at least 1 year after discontinuing therapy
with these agents. In summary, TDF, ATV/r and
LPV/r were independent predictors of chronic
renal impairment in HIV-infected individuals
without pre-existing impaired renal function.
In a subsequent analysis of data from the
D:A:D study, 35,192 patients with HIV infection
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were followed up for several years [62]. Patients
without advanced CKD or end-stage renal
disease (ESRD) at the start of the study
(January 2004) were included and followed up
until a diagnosis of advanced CKD/ESRD was
made 6 months after the final study visit or
until January 2012. Advanced CKD was defined
as two eCC results of\30 mL/min/
1.73 m2 C3 months apart and patients with
ESRD were on dialysis for C3 months or had
undergone renal transplantation. Poisson
regression models were used to investigate
ARV discontinuation rates in relation to the
latest eCC assessment, and to identify variables
associated with the development of advanced
CKD/ESRD; the model included adjustments for
various factors, including age, gender, ethnicity,
HIV RNA level, CD4? cell count, traditional risk
factors (e.g., hypertension, diabetes), and
treatment with TDF and PIs.
Over the median follow-up period of
6.2 years, 135 individuals (0.4%) developed
CKD/ESRD (CDK, n = 114; and ESRD, n = 21)
(IR 0.67 per 1,000 person-years). At the 5-year
evaluation, progression to advanced CKD/ESRD
was estimated to be 0.32 per 1,000 person-years.
As the eCC declined, rates of switching from
ATV/r, LPV/r, and TDF increased, but this was
especially the case for TDF (Fig. 2). After
adjustment, those exposed, but currently off
TDF, had similar IRRs for advanced CKD
compared to those unexposed, while those
currently on TDF had reduced rates (note: that
those with reduced eCC while on TDF were
more likely to discontinue). None of the other
ARV drugs included in the analysis showed a
significant effect on IRRs for CKD/ESRD.
However, the adjusted IRR of CKD/ESRD was
increased with diabetes, hypertension, lower
baseline eGFR, and decreased in those who had
>90 50–60 <30 




































TDF: 21,899 persons on TDF at baseline or start during follow-up; 9,141 stop during 63,698 py
ATV/r: 7,857 persons on ATV/r at baseline or start during follow-up; 4,709 stop during 19,371 py
LPV/r: 8,038 persons on LPV/r at baseline or start during follow-up; 5,387 stop during 20,449 py
Fig. 2 ARV discontinuation according to current
estimated creatinine clearance level in the D:A:D study.
Models were adjusted for CD4 count nadir, gender,
ethnicity, HIV transmission risk, enrollment cohort and
prior acquired immune deﬁciency syndrome (all at baseline)
and hepatitis B virus, hepatitis C virus, smoking status,
hypertension, diabetes, cardiovascular events, age, and CD4
count (as time-updated values). Adapted from Ryom et al.
[62]. ARV antiretroviral, ATV/r ritonavir-boosted atazanavir,
CI conﬁdence interval, HIV human immunodeﬁciency virus,
LPV/r ritonavir-boosted lopinavir, py person-years, TDF
tenofovir disoproxil fumarate
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never smoked and in patients with higher
current CD4 counts. Of interest, as eCC fell so
did rates of ARV discontinuation/switching,
which would suggest that in a real-life setting,
clinicians actively monitor renal function and
largely prevent advanced ARV-related renal
disease.
ATV, LPV, FPV, SQV, IDV, nelfinavir: In a
retrospective cohort analysis, patients
(n = 7,378) from seven large HIV reference
centers (with prospective HIV databases) in
France were assessed for risk factors for CKD
from 1993 to 2006 [63]. The primary outcome
was the time to CKD, which was defined as two
consecutive measures of eGFR B60 mL/min/
1.73 m2 over C3 months (MDRD equation
without the term for race as ethnicity data was
unavailable). Factors predictive of time to CKD
were assessed using a Cox proportional hazards
model with delayed entry. In this study, time of
entry was defined as the date of the first
creatinine measurement. In real-life cohort
data, it is common for patients to enter the
study at varying time points. There is a
substantial possibility that patients with
delayed entries may have very different hazard
ratios for CKD compared with those entering at
the start of the study period; for example, only
older potentially more nephrotoxic ARVs being
available earlier versus newer potentially less
nephrotoxic agents being available later.
Allowing for delayed entry enables patients
experiencing CKD events within a similar time
period, during which ARV use is likely to have
been more consistent, to be compared with
each other. Patients entering and experiencing
CKD events later in the study, during which
ARV use may have changed, will also be
compared with each other. Thus, hazard ratios
for CKD events using this methodology will
take into account changing patterns of ARV use
over time. A wide variety of ARVs, including PIs
(ATV, LPV, FPV, SQV, IDV, nelfinavir), were
assessed for their potential association with
CKD. CKD was identified in 4.7% of patients.
In multivariate analyses, significant risk factors
for CKD were the occurrence of AKI,
hypertension, recent exposure to IDV, TDF or
ABC, and past exposure to TDF. None of the
other PIs tested were associated with CKD.
However, the potential interaction between
TDF and PIs was not assessed.
Studies analyzing PIs as a class effect.
Participants with HIV infection initiating
TDF in combination with a PI- or NNRTI-based
regimen were assessed in a large cohort study
(NA-ACCORD), reported as an abstract [64]. At
baseline, most of the 5,801 patients were
treatment-experienced, and 3,575 patients
initiated treatment with TDF in combination
with a PI-based regimen. During 2.3 years
(TDF ? PI) and 2.1 years (TDF ? NNRTI) of
treatment, the median change in eGFR was -
1%/year for both groups (adjusting for a history
of hypertension and diabetes, age[50 years,
and Black race). Among individuals with the
most marked declines in renal function of C8%/
year, those who received treatment with
TDF ? PI had the most marked decreases in
eGFR. However, at baseline, the TDF ? PI group
was more likely to be of Black race (P\0.01)
and older in age (P = 0.03); given that both
factors are associated with a higher risk of CKD,
the clinical significance of changes in renal
function in this study cannot be determined.
In a prospective study using data from the
Swiss HIV Cohort Study database, patients were
identified who were ARV-naı¨ve or whose ARV
therapy had been interrupted for C12 months
(n = 1,078) [65]. Selected patients were required
to have a baseline eCC (CG equation) and at
least two eCC values after starting or restarting
combination ARV therapy. The authors stated
that the CG equation was preferred over the
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Table 4 Discontinuation rates due to renal AEs from randomized trials in treatment-naı¨ve patients examining TDF plus a




due to renal AE (%)
Reason(s)
TDF ? boosted PI
ABT-730 (LPV/r) [73] 664 96 0
ARTEMIS (DRV/r or LPV/r) [74] 689 96 0
GEMINI (SQV/r or LPV/r) [75] 337 48 0
ARTEN (ATV/r) [76] 193 48 0
CASTLE (ATV/r) [42] 440 96 0.2% Fanconi syndrome
CASTLE (LPV/r) [42] 443 96 0.2% Proteinuria
HEAT (LPV/r) [77] 345 96 0.6% ARF
ABT-418 (LPV/r) [78] 190 96 1.1% ARF
GS-US–164–0115 (BATON) (ATV/r) [79] 100 48 1.0% Grade 2 creatinine
GS-US-216-0114 (ATV/r) [33] 348 48 1.4% : serum creatinine
Proximal tubulopathy
GS-US-216-0114 (ATV/cobicistat) [33] 344 48 1.7% : serum creatinine
Proximal tubulopathy
ACTG 5202 (ATV/r) [38] 464 96 1.3% ; creatinine clearance
ALERT (ATV/r) [43] 53 48 0
ALERT (FPV/r) [43] 53 48 5.7% GFR\50 mL/min
TDF ? INSTI or NNRTI
STARTMRK (RAL or EFV) [80] 563 48 Not reported
QDMRK (RAL) [81] 770 48 Not reported
GS–99–903 (EFV) [82] 299 144 0
GS–01–934 (EFV) [83] 257 144 0
ECHO/THRIVE (RPV or EFV) [84] 1096 96 0
ASSERT (EFV) [85] 193 96 0
ARTEN (NVP) [76] 376 48 0.3% ; GFR
ACTG 5202 (EFV) 461 96 0.7% ; creatinine clearance
AE adverse event, ATV/r ritonavir-boosted atazanavir, DRV/r ritonavir-boosted darunavir, EFV efavirenz, FPV/r ritonavir-
boosted fosamprenavir, GFR glomerular ﬁltration rate, INSTI integrase strand inhibitor, LPV/r ritonavir-boosted lopinavir,
NNRTI non-nucleoside(nucleotide) reverse-transcriptase inhibitor, NVP nevirapine, PI protease inhibitor, RAL raltegravir,
RPV rilpivirine, SQV/r ritonavir-boosted saquinavir, TDF tenofovir disoproxil fumarate
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MDRD equation as they considered it to correct
for weight changes during the period of the
study (the MDRD equation was used in
secondary sensitivity analyses). However, the
MDRD equation adjusts for body surface area,
which is influenced by changes in weight. Over
24 months, TDF-containing regimes were
associated with significant median reductions
in eCC and shorter time to a sustained 10 mL/
min reduction in eCC, regardless of treatment
experience. In multivariate Cox proportional
hazards models, TDF use (HR 1.84; 95% CI
1.35–2.51) and boosted PI use (HR 1.71; 95% CI
1.30–2.24) were significantly associated with
time to a sustained 10 mL/min reduction in
eCC; other significant associations were female
gender, diabetes, and higher baseline eCC. The
interaction term between TDF and boosted PI
use was not significant (P = 0.2). Consistent
results were reported using the DMDRD
equation. However, follow-up was too short to
assess whether initial reductions in eCC were
stable or progressive.
The ANRS CO3 Aquitaine Cohort study,
investigated the prevalence of renal
impairment, defined as an eCC (CG equation)
of 60–90 mL/min (mild), 30–60 mL/min
(moderate), 15–30 mL/min (severe) or\15 mL/
min (end-stage), in a cross-sectional
retrospective survey of a French hospital-based
cohort of patients with HIV infection
(n = 2,588) [6]. Across the study cohort, the
overall prevalence of renal impairment was very
high at 39%; mild, moderate, severe, and ESRD
were present in 34.2%, 4.4%, 0.3%, and, 0.2% of
patients, respectively. In logistic regression
models, increasing duration of TDF exposure
was associated with an increased risk of mild
renal impairment, whereas PIs (with the
exception of IDV) were not associated with
this outcome. However, no analysis of the
potential interaction between TDF and PIs was
presented. Other factors associated with an
increased risk of renal impairment were female
gender, older age, body mass index
(BMI)\22 kg/m2, and hypertension.
In a further prospective analysis of the ANRS
CO3 Aquitaine Cohort, patients with HIV-1
infection and a baseline eGFR (MDRD equation)
of[60 mL/min/1.73 m2 (n = 2,692) were
followed up for a median duration of 3.4 years
[66]. At the end of the follow-up period, 95% of
patients had received ARV therapy and among
these patients 35% had received TDF in
combination with a PI/r (ATV 41%, LPV 35%,
FPV 11%, SQV 4%, others 9%) for[6 months.
The determinants of CKD, defined as an eGFR
of\60 mL/min/1.73 m2 on two consecutive
occasions C3 months apart, were assessed
using a Poisson regression model. The IR
of CKD, defined as an eGFR of\60 mL/
min/1.73 m2 on two consecutive
occasions C3 months apart, was low at 1.01
cases per 100 patient-years. In univariate
Poisson regression analysis, ever having been
exposed to a PI was associated with an increased
incidence of CKD (IRR 3.0; 95% CI 1.5, 5.7;
P = 0.008). In multivariate analyses, an
independent effect of PIs was no longer
evident, but exposure to a PI in combination
with TDF for at least 6 months appeared to
increase the incidence of CKD [IRR for TDF
without PI for C6 months 1.8 (95% CI 1.0, 3.3)
vs. IRR for TDF with PI for C6 months 3.5 (95%
CI 2.1, 6.1); P value for difference = 0.0006].
Other associated risk factors were ever having
been exposed to TDF (IRR 2.5; 95% CI 1.5, 4.1;
P = 0.0002), female gender, older age, low
baseline eGFR, diabetes, hyperlipidemia, and
low CD4 count. However, the median exposure
to PIs (3.6 years) was longer than that for TDF
(1.9 years) making interpretation of interactive
effects difficult. The authors suggested that a
combination of TDF with a PI requires careful
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monitoring to prevent the development of CKD
and that further studies are required to identify
if the effect varies across individual PIs.
Level 3 Evidence (Case–Control Studies)
No case–control multicenter studies of
sufficient sample size to meet the inclusion
criteria of this review were identified.
Discontinuation Rates Due to Renal AEs
in RCTs Involving PIs and Comparators
Discontinuation rates due to renal AEs from
clinical trials in treatment-naı¨ve patients
receiving TDF plus a boosted PI versus trials in
treatment-naı¨ve patients receiving TDF plus an
integrase strand inhibitor (INSTI) or NNRTI are
summarized in Table 4. Discontinuation rates
due to renal AEs with TDF plus LPV/r or ATV/r
were low and ranged from 0 to 1.2%, and were
similar to those with TDF plus an INSTI or
NNRTI (0–0.7%). A single study in patients
receiving FPV showed a discontinuation rate
of 5.7% due to eGFR falling to below 50 mL/
min.
DISCUSSION
Only four reports describing three studies were
available that fell under the category of Level 1
evidence. All examined ATV in treatment-naı¨ve
patients who were also receiving concomitant
TDF, and all used non-IDMS-standardized
serum creatinine measurements and associated
CG or MDRD estimating equations. Initial
decreases in serum creatinine occurred in ATV/
r ? TDF-based regimens, but not in EFV ? TDF-
based regimens, that were nevertheless non-
progressive after 8 weeks and up to 96 weeks.
COBI as a pharmacoenhancer of ATV or EVG
appeared to be associated with greater initial
drops in eCC or eGFR vs ATV/r. Level 1 evidence
would suggest that the changes in serum
creatinine, eCC, or eGFR with ATV are largely
determined by the inhibition of renal tubular
creatinine secretion by RTV or COBI
pharmacoenhancement rather than by any
nephrotoxic effect of ATV. However, given
that all regimens in these Level 1 studies
contained TDF, an interaction with TDF can
neither be assumed nor ruled out.
Regarding Level 2 RCT evidence, most
studies were small (\100 patients per arm) and
only one evaluated changes in proteinuria.
These studies generally showed reductions in
eGFR with PIs in combination with TDF. Of the
larger studies reviewed, A5202 showed
reductions in ATV/r in combination with TDF,
but in ARIES, in which TDF was not used, no
changes in eGFR were demonstrated with either
RTV-boosted or unboosted ATV.
Taken together, the RCT data would suggest
little evidence for an independent effect of PIs
on decline in renal function, especially since
studies examining changes in proteinuria with
PIs without concomitant TDF use have shown
no change in proteinuria with treatment [67,
68]. Evidence for an interactive effect of PIs with
TDF on initial but non-progressive declines in
eGFR was consistent and was demonstrated
across ATV and LPV; however, few studies
conducted multivariate analyses and of those
that did, three showed that the PI effect
remained significant after adjustment [39, 40,
47] and the fourth that it was no longer
significant [44]. Regarding a potential
mechanism for this PI–TDF interaction, the
post hoc ACTG A5142 analysis suggested that
LPV/r inhibition of drug transporters may
increase TDF exposures [45]. It should also be
noted that most RCTs excluded patients with
baseline eGFR\70 mL/min, and that only one
Level 2 RCT used IDMS-standardized creatinine
measurements, limiting the generalizability of
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these findings to the wider population of
patients with HIV-1 infection. RCT data on
DRV was insufficient to draw conclusions.
A vast literature constituting Level 2
observational evidence was identified, much of
low quality. Therefore, to reduce bias, studies
were only reviewed if they included more than
1,000 patients from more than 1 study center.
In prospective cohorts of treatment-naı¨ve
patients with well-preserved renal function
[58], ARV therapy overall was associated with a
slower rate of decline in eGFR over time, in
parallel with increases in CD4 count and
decreases in HIV-1 RNA load. However, risk for
CKD was increased with amprenavir/r and LPV/
r in combination with TDF but not for ATV/r or
LPV/r without TDF. In populations with greater
proportions of patients having baseline renal
impairment [55, 58, 59], PIs independently or in
combination with TDF were associated with an
increased risk of CKD. In prospective studies of
patients with mixed treatment experience,
consistent evidence emerged for an increased
risk of CKD with TDF, but the clinical
significance of changes in renal function with
other PIs was less certain. Data from the
EuroSIDA study indicated that any or
cumulative exposure to TDF, ATV, and to a
lesser extent LPV/r, was associated with an
increased incidence of CKD on multivariate
analyses [19, 60]. Testing possible interactions
between TDF and PIs through censoring
confirmed an independent effect of TDF, but
could not provide certainty as to whether the
effect of PIs was independent or better
explained by an interaction with TDF. The
increased risk of CKD with ATV, LPV/r, and
TDF, however, returned to levels seen in
patients never exposed to these agents
immediately following discontinuation of ATV
or LPV, and after 1 year following
discontinuation of TDF. Data from the D:A:D
study in patients with normal baseline renal
function demonstrated that the increased risk
of CKD with TDF, ATV/r and LPV/r was
decreased to unity 1 year after discontinuing
these ARVs [61]. These findings from the
EuroSIDA and D:A:D cohorts could either
suggest that the potential nephrotoxicity of
these agents was reversible on cessation, or that
for individuals who have not already developed
CKD, the rate of developing CKD was reduced
after cessation. Further analysis of appropriately
designed long-term studies is required to resolve
this question. A subsequent analysis of the
D:A:D cohort suggested that ATV/r and LPV/r
were not, however, associated with the
development of advanced CKD or ESRD [62];
discontinuation analyses by current eGFR level
suggested that TDF discontinuation may protect
against the development of advanced CKD/
ESRD in these patients. Data from other
cohorts provided conflicting conclusions as to
whether the increased risk of CKD was
attributable to an independent effect of PIs as
suggested in the Swiss Cohort study [65] or only
in interaction with TDF as suggested in the CO3
Aquitaine Cohort study [66].
Taken together, the prospective
observational data would suggest that
currently used PIs such as ATV/r or LPV/r are
associated with modest reductions in eGFR,
which may or may not be associated with
interactions with TDF, but do not appear to
lead to advanced CKD/ESRD. Data on other
currently used PIs such as DRV/r were
completely lacking. Data from retrospective
observational studies provided similar findings
to those from prospective studies.
An initial drop in eGFR in the short term
with stabilization thereafter was seen in many
studies. Longer term studies are required to
ascertain whether the rate of decline reached
after leveling off is equivalent to the rate of
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decline expected for age or whether the rate of
decline remains elevated even when taking into
account age and other HIV-related and general
comorbidities. However, the general
assumption that GFR decreases with age in a
regular manner might be correct at a population
level but not necessarily at the individual level
where factors such as hyperfiltration may alter
GFR estimates [69]. Therefore, short-term
changes in estimates of renal function have to
be viewed with some caution if not paralleled
by other signs of renal dysfunction.
Differences in the interpretation of renal
function changes between estimating
equations were evident, particularly between
the newer cystatin-C-based methods [40, 44, 67]
and the older creatinine-based methods, which
could have arisen from a number of different
mechanisms. The initial decline in eGFR
followed by stabilization observed in many
studies using creatinine-based estimating
equations, raise the possibility that the greater
changes in eGFR with boosted PIs might be due
to RTV- or COBI- induced inhibition of the
renal tubular transport of creatinine rather than
any effect on renal function per se. Given the
fact that cystatin-C is elevated in untreated HIV
infection and decreases on ART initiation [70],
the cystatin-C-based equations actually led to
an increase in eGFR in ACTG 5224s [67] and in
another study [44]. This equation is probably
not suitable for monitoring renal function in
the dynamic situation of ART initiation, but
might be suitable later on when HIV replication
is suppressed. Only 2 of the reviewed studies
provided data beyond creatinine, cystatin-C or
their associated estimating equations, such as
changes in proteinuria [40, 67]; thus, the
clinical significance of these changes in eGFR
remains uncertain.
The discontinuation rate from clinical trials
due to renal events was very low and
comparable between PIs ? TDF versus INSTI or
NNRTI ? TDF, suggesting that PIs as a class
(with the exception of IDV) do not cause
clinically significant renal impairment. These
RCT data are supported by analyses of
discontinuations due to renal events in cohort
studies, which indicate that the risk of CKD
with LPV/r and ATV decreased on cessation of
therapy, irrespective of baseline eGFR status [60,
61]. Taken together, these findings from RCTs
and real-life cohort studies would suggest that
the commonly used PIs, LPV/r, and ATV are not
associated with progressive impairment in renal
function.
This systematic review has a number of
strengths. To our knowledge, this represents
the most comprehensive review of the
potential association of PIs with CKD
undertaken. We attempted to summarize all
available RCT data and, in order to reduce bias
from small observational studies or case series,
pre-defined criteria were established to select
only those observational studies least likely to be
subject to bias. We also structured our evaluation
using the OCEBM levels of evidence criteria to
allow readers to easily assess the strength of
available evidence.
A number of limitations, inherent to the
nature of the data being evaluated, were also
noted. The available data on CKD were heavily
influenced by year of introduction of ARVs,
which could introduce bias; thus, many RCTs
and cohort studies were identified using ATV/r or
LPV/r, but only a single small RCT using DRV/r.
RCT data should have been less subject to bias
owing to the process of randomization; however,
many of these trials were of small sample size, of
short duration (48 weeks or less), showed a low
rate of renal events, and few conducted
multivariate analyses. All but one of the RCTs
reviewed were in treatment-naı¨ve patients,
making it difficult to assess changes in renal
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function, since there is an overlap between
improvement in kidney function secondary to
virological suppression and possible nephrotoxic
effects of ARVs. Examining changes in renal
function in treatment-experienced patients
switched to a PI-containing regimen potentially
provides useful information on changes
attributable to PIs; however, renal function in
this context is also difficult to assess because of
the potential continuing nephrotoxic effects of
prior ARV exposure. Only one RCT examined a
PI-switch strategy, but the observed changes
were uninterpretable owing to methodological
difficulties [54]. Most of the published literature
on renal function with ARVs was in the form of
observational studies, the majority of which
were small studies from single centers.
Although our selection criteria excluded single-
center studies with less than 1,000 participants,
not all of the selected studies performed
multivariate analyses, which in the
observational study setting is essential to avoid
potential bias arising from the lack of
randomization. However, despite the use of
multivariate analysis, it is nearly impossible to
adequately control for all potential sources of
baseline imbalances in observational studies. In
addition, observational studies can be associated
with other forms of bias or difficulties in
interpretation as follows. Channeling bias may
have influenced the assessment of changes in
renal function for some PIs. For example,
because ATV/r has a more favorable lipid profile
than LPV/r, ATV/r may have been used more
frequently in patients with metabolic/
cardiovascular diseases (i.e., conditions that
pre-dispose to kidney disease). In addition,
ATV/r is commonly used in combination with
TDF. The observational studies employed a wide
range of statistical methodologies, ranging from
Poisson regression models to Cox proportional
hazards models with or without delayed entry.
Flandre et al. [63] have argued that Cox
proportional hazards models with delayed entry
are essential to accurately assess CKD risk
because of the changing pattern of ARV
availability over time and the influence of
cumulative exposure to prior ARVs. Thus, there
are significant problems to establishing causality
in observational studies with an associated risk of
misattributing the development of CKD to ARV
use. The majority of studies either used the CG
equation (not best suited for assessing renal
function in patients with HIV-1 infection and
not IDMS-validated), or used the original MDRD
equation (not IDMS-validated). The variability in
eCC measurement in studies using the CG
equation or in eGFR using the original MDRD
equation, limits the interpretation of many of
these studies; for example, the D:A:D cohort
study, which used the CG equation in patients
with normal baseline renal function for whom
variability would be expected to be greater.
Although some studies employed estimating
equations that have been validated using IDMS
standardization, CKD-EPI [39, 40, 44, 58, 60, 67]
and MDRD-4 [43, 44, 55], only one of these
studies specifically mentioned in the methods
section that IDMS standardization of serum
creatinine measurement had been employed
[40]. Of note, many of the source publications
described eGFR to be measured by the CG
equation when this equation represents a
measurement of eCC rather than eGFR; under
these instances, we described these studies as
having measured eCC. Finally, only two studies
examined rapid progression of CKD with ARVs
[56, 64].
CONCLUSIONS
This review identified limited evidence that
currently used PIs, such as LPV/r and ATV/r
were associated with non-progressive
44 Infect Dis Ther (2015) 4:15–50
reductions in eGFR without an elevated risk
for the development of advanced CKD or
ESRD. Whether the changes in eGFR with PIs
were independent, or as a result of inhibition
of renal tubular creatinine secretion by RTV
or COBI pharmacoenhancement, or as a
result of interactions with other ARVs such
as TDF could not be established with
certainty. Very few of the reviewed studies
included a broader range of renal function
assessments beyond serum creatinine, eCC/
eGFR estimating equations; thus, the clinical
significance of these findings remains
uncertain. Further long-term clinical trials,
employing a wide range of appropriate
renal function assessments (e.g., IDMS-
standardized creatinine measurement, IDMS-
validated eGFR equations, ACR) and specific
renal endpoints (e.g., rapid progression of
CKD) analyzed with sufficient statistical
power, are required to fully understand any
potential nephrotoxic effects of PIs. However,
to place these findings in context, it is
important to highlight that a number of
studies demonstrated that, overall, ARV
therapy reduced the risk for CKD, and that
HIV-related factors, such as low CD4 or high
viral load, hepatitis coinfection, previous
episodes of AKI, or traditional risk factors,
such as advancing age, female gender,
hypertension and diabetes significantly
increased risk for CKD. Thus, potential
changes in renal function with PIs should
be assessed within the framework of the
overall benefit of ARV therapy and the
importance of addressing associated non-
ARV therapy-related risk factors. Finally, in
clinical practice regular monitoring of renal
function should be undertaken for all
patients with HIV infection, regardless of
ARV therapy usage.
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